The Hemodynamic and Coagulant Effects of DDAVP Are Specific Extrarenal V2- Receptor Responses

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-1-4615-2922-4_10
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• New category of vasopressin receptor in the central nervous system. Evidence that this receptor mediates the release of a humoral factor VIII-mobilizing principle.

  2009cited by this paper
• Literature abstracts

  2004cited by this paper
• Variations on a Theme

  1993cited by this paper
• Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).

  1992cited by this paper
• Diversity of G proteins in signal transduction

  1991cited by this paper
• Derivatives of somatic cell hybrids which carry the human gene locus for nephrogenic diabetes insipidus (NDI) express functional vasopressin renal V2-type receptors.

  1990cited by this paper
• Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.

  1990cited by this paper
• Normal homeostasis of fibrinolysis in nephrogenic diabetes insipidus in spite of defective V2‐ receptor‐mediated responses of tissue plasminogen activator release

  1990cited by this paper
• DDAVP-induced release of von Willebrand factor from endothelial cells in vitro: the effect of plasma and blood cells.

  1990cited by this paper
• The second-messenger system for peptide hormones.

  1989cited by this paper
• Peripheral vasodilatation induced by a vasopressin analogue with selective V2-agonism in dogs.

  1989cited by this paper
• Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism.

  1989cited by this paper
• Pseudohypoparathyroidism: clinical and molecular aspects.

  1989cited by this paper
• Vasopressin and Anterior Pituitary Function

  1989cited by this paper
• Vasopressin and Brain Function

  1989cited by this paper
• The Metabolic basis of inherited disease

  1989cited by this paper
• Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor.

  1989cited by this paper
• Effects of a specific antidiuretic agonist on cardiac output and its distribution in intact and anephric dogs.

  1988cited by this paper
• Characterization of acute hemodynamic effects of antidiuretic agonists in conscious dogs.

  1988cited by this paper
• Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.

  1988cited by this paper
• Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders.

  1988cited by this paper
• Arginine vasopressin as a thyrotropin-releasing hormone.

  1987cited by this paper
• Endothelium and responsiveness of vascular smooth muscle.

  1987cited by this paper
• HORMONAL AND CARDIOVASCULAR RESPONSES TO DDAVP IN MAN

  1986cited by this paper
• Evidence for normal antidiuretic responses to endogenous and exogenous arginine vasopressin in patients with guanine nucleotide-binding stimulatory protein-deficient pseudohypoparathyroidism.

  1986cited by this paper
• Dynamics of nucleotides in distal nephron of mice with nephrogenic diabetes insipidus.

  1986cited by this paper
• Diabetes insipidus in man

  1985cited by this paper
• Hemodynamic effects of neurohypophyseal peptides with antidiuretic activity in dogs.

  1985cited by this paper
• Nephrogenic Diabetes insipidus in Children

  1985cited by this paper
• Vasopressin Causes Endothelium‐Dependent Relaxations of the Canine Basilar Artery

  1984cited by this paper
• Research fraud: False data confessed

  1983cited by this paper
• Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.

  1983cited by this paper
• Absence of overlapping resistance to vasopressin and parathyroid hormone in patients with nephrogenic diabetes insipidus and pseudohypoparathyroidism.

  1982cited by this paper
• Effects of Various Agents on Ristocetin-Willebrand Factor Activity in Long-Term Cultures of von Willebrand and Normal Human Umbilical Vein Endothelial Cells

  1981cited by this paper
• Monographs on Endocrinology

  1981cited by this paper
• Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin.

  1979cited by this paper
• Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs

  1975cited by this paper
• Endocrine and genetic diseases of childhood and adolescence

  1975cited by this paper
• Hepatic action of vasopressin: Lack of a role for adenosine‐3′,5′‐cyclic monophosphate

  1974cited by this paper
• Sex Chromosomes and Sex-Linked Genes

  1967cited by this paper
• The secretion of urine as studied on the isolated kidney

  1925cited by this paper
• On the Physiological Action of Extracts of Pituitary Body and certain other Glandular Organs

  1895cited by this paper

• Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans.

  2005influential citation
• Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system.

  2003cites this paper
• The Vasopressin Antagonist Sk&F 105494 Inhibits Desmopressin-Stimulated Clotting Factor Release in Vivo

  1993cites this paper